Patient with diabetes after acute coronary event. How to improve forecast?
https://doi.org/10.33667/2078-5631-2019-1-3(378)-6-11
Abstract
Patients with diabetes mellitus are characterized by a higher risk of developing atherothrombotic events than patients without diabetes. One of the reasons for this is the high reactivity and rate of platelet metabolism. The role of aspirin in the prevention of cardiovascular events in patients with diabetes without a history of atherothrombotic events is unclear. In patients with a history of thromboischemic events, aspirin is useful for cardiovascular prophylaxis. Available data suggest that patients with diabetes and acute coronary syndrome (ACS) will benefit more from using more aggressive antiplatelet drugs than clopidogrel (in addition to aspirin), which will reduce the ischemic risk for patients with diabetes of equal or greater degree compared with patients without diabetes. These drugs include ticagrelor (in patients with ACS, regardless of the initial treatment strategy) and prasugrel (in patients with an invasive treatment strategy). For patients with diabetes, high ischemic and low hemorrhagic risks, prolonging double antiplatelet therapy for more than a year with a reduced dose of ticagrelor (60 mg twice a day) can be accompanied by a decrease in ischemic risk.
About the Author
O. L. Barbarash
ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»; ФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
References
1. Барбараш О. Л., Груздева О. В., Акбашева О.Е. и соавт. Клинико-биохимические предикторы манифестации сахарного диабета после перенесенного инфаркта миокарда. Российский кардиологический журнал. 2014; № 107; 87-94.
2. Guariguata L., Whiting D. R., Hambleton I., et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103: 137-149.
3. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013; 34 (39): 3035-3087.
4. Gomez F. L., Moreira Andres M. N. Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus. Med Clin. 2008; 130: 641-644.
5. Петрик Г. Г., Павлищук С. А., Космачева Е.Д. Сахарный диабет и кардиоваскулярные нарушения: фокус на гемостаз. Российский кардиологический журнал. 2014; № 3 (107): 114-118.
6. Vinik A. I., Erbas T., Park T. S., et al. Platelet Dysfunction in Type 2 Diabetes. Diabetes Care. 2001; 24 (8): 1476-1485.
7. Santilli F., Simeone P., Liani R., et al. Platelets and diabetes mellitus. Prostaglandins Other Lipid Mediat. 2015; 120: 28-39.
8. Kim J. H., Bae H. Y., Kim S. Y. Clinical marker of platelet hyperreactivity in diabetes mellitus. Diabetes Metab J. 2013; 37 (6): 423-428.
9. Keating F. K., Sobel B. E., Schneider D. J. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol. 2003; 92 (11): 1362-1365.
10. Aref S., Sakrana M., Hafez A.A., et al. Soluble P-selectin levels in diabetes mellitus patients with coronary artery disease. Hematology. 2005; 10 (3):183-187.
11. Guthikonda S., Alviar C. L., Vaduganathan M., et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. JACC. 2008; 52 (9): 743-749.
12. Belostocki K., Pricop L., Redecha P. B., et al. Infliximab treatment shifts the balance between stimulatory and inhibitory Fc-receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis & Rheumatism. 2008; 58 (2): 384-388.
13. Бондаренко И. З., Ширшина И. А. Механизмы тромбообразования, ассоциированные с сахарным диабетом: что определяет прогноз интервенционного вмешательства? Сахарный диабет. 2013; 3: 58-63.
14. Valgimigli M., Bueno H., Byrne R., et. al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39 (3): 213-260.
15. Новиков В. И., Новиков К. Ю. Антиагреганты при сахарном диабете: современные подходы и перспективы профилактики ишемической болезни сердца. Consilium Medicum. 2018; 04: 16-23.
16. Gaziano J.M., Brotons C., Coppolecchia R., et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392: 1036-1046.
17. McNeil J.J., Wolfe R., Woodset R. L., et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018; 379: 1509-1518.
18. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus The ASCEND Study Collaborative Group. N Engl J Med. 2018; 379: 1529-1539.
19. Dillinger J. G., Drissa A., Sideris G. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am. Heart J., 2012; 164 (4): 600.
20. Bethel M. A., Harrison P., Sourij H., et al. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. DiabetMed. 2016; 33 (2): 224-230.
21. Aspirin Twice a Day in Patients with Diabetes and Acute Coronary Syndrome (ANDAMAN). clinicaltrials.gov/ct2/show/study/ NCT02520921. Accessed Jan 15th, 2019.
22. Schrör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets. 1993; 4 (5): 252-261.
23. The Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.
24. Yusuf S., Mehta S. R., Zhao F. Et al. For the CURE Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003; 107: 966-972.
25. Steinhubl S. R., Berger P. B., Mann J. T.3rd. et al. For CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411-2420.
26. Hall H. M., Banerjee S., McGuire D. K. Variability of clopidogrel response in patients with type 2 diabetes mellitus. Diabet Vasc Dis Research. 2011; 8 (4): 245-253.
27. Bhatt D. L., Flather M.D., Hacke W. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J am Coll Cardiol. 2007; 47: 1982-1988.
28. Andersson C., Lyngbek S., Nguyen C. D., et al. Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. JAMA. 2012; 308 (9): 882-889.
29. Angiolillo D. J., Shoemaker S. B., Desai B., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007; 115 (6): 708-716.
30. Tantry U. S., Bliden K. P., Gurbel P. A. Prasugrel. Expert Opin Investig Drugs. 2006; 15 (12): 1627-1633.
31. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357 (20): 2001-2015.
32. Wiviott S.D., Braunwald E., Angiolillo D.J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008; 118 (16): 1626-1636.
33. Teng R. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet. 2015; 54 (11): 1125-1138.
34. Wallentin L., Becker R. C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361 (11): 1045-1057.
35. James S., Angiolillo D. J., Cornel J. H., et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010; 31: 3006-3016.
36. Bonaca M. P., Bhatt D., Cohen M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-1800.
37. Bhatt D. L., Bonaca M. P., Bansilal S., et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016; 67: 2732-2740.
38. Thomas M. R., Angiolillo D. J., Bonaca M. P., et al. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost. 2017; 117 (5): 940-947.
39. James S., Angiolillo D. J., Cornel J. H., et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010; 31 (24): 3006-3016.
40. Laine M., Frère C., Toesca R., et al. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. Thromb Haemost. 2014; 111 (2): 273-278.
Review
For citations:
Barbarash O.L. Patient with diabetes after acute coronary event. How to improve forecast? Medical alphabet. 2019;1(3):6-11. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-3(378)-6-11
Views:
631
Email this article 